✨ Your Portfolio is fetched and updated from zerodha.
Market Cap
₹1,606 Cr.
P/E
44.06
About
Beta Drugs, a part of the Adley Group, specializes in developing, manufacturing, and marketing oncology products like anti-cancer tablets, capsules, injections, and lyophilized injections. With a port… Read more
Beta Drugs, a part of the Adley Group, specializes in developing, manufacturing, and marketing… Read more
Low
892
52W Range
High
1985
Quick View
  • 1d
  • 1m
  • 6m
  • YTD
  • 1y
  • 3y
  • 5y
  • 10y
  • max

Company Timeline

Custom financial statement
Edit rows
Forensics

11 Yes

Positive for this company

3 Neutral

Neutral for this company

2 No

Negative for this company

1 No Data

Insufficient data to analyse

Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Peer Comparison
FAQs on Beta Drugs Ltd. Business

Beta Drugs, a part of Adley Group, specializes in manufacturing oncology products like anti-cancer tablets, capsules, injections, and lyophilized injections. With a portfolio of over 50 products, it caters to the treatment of various cancer diseases.

Beta Drugs major competitors are Zota Health Care, Bliss GVS Pharma, Lincoln Pharma, Panacea Biotec, Syncom Formulations, Bharat Parenterals, Jagsonpal Pharma.
Market Cap of Beta Drugs is ₹1,627 Crs.
While the median market cap of its peers are ₹1,442 Crs.

Beta Drugs seems to be financially stable compared to its competitors.
The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

Company Filing
2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
Annual Report FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
Earnings Release Mar Jun Sep Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
Investor Presentation Mar Jun Sep Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
Conference Call Mar Jun Sep Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
Conference Call SummaryCon Call Summary Mar Jun Sep Mar Jun Sep Dec Jun Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
Discussions & Analysis